Arbutus Biopharma Corporation (ABUS) Q4 2024 Annual Earnings
ABUS·Reported March 27, 2025·Before market open
Arbutus Biopharma Corporation reported Q4 2024 revenue of $1.6M, missed analyst consensus of $2.3M by $683.0K. Diluted EPS came in at $-0.07, beat the $-0.08 consensus by $0.01.
Revenue
$1.6Mmissed by $683.0K
Consensus: $2.3MDiluted EPS
$-0.07beat by $0.01
Consensus: $-0.08
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Arbutus Biopharma Corporation's Q4 2024 earnings report.
Arbutus Biopharma Corporation (ABUS) reported Q4 2024 earnings on March 27, 2025 before market open.
Arbutus Biopharma Corporation reported revenue of $1.6M and diluted EPS of $-0.07 for Q4 2024.
Revenue missed the consensus estimate of $2.3M by $683.0K. EPS beat the consensus estimate of $-0.08 by $0.01.
You can read the 10-K periodic report (0001447028-25-000083) directly on SEC EDGAR. The filing index links above go to sec.gov.